Provider Briefing: Solosec Availability in 2026

If your patients are reporting difficulty filling Solosec (Secnidazole) prescriptions, they're not alone. Throughout 2025 and into 2026, Solosec — the only FDA-approved single-dose oral treatment for bacterial vaginosis — has faced persistent availability challenges at the retail pharmacy level.

This briefing covers what you need to know as a prescriber: the current shortage timeline, clinical implications, alternative therapies, cost considerations, and tools to help your patients access their medications.

Shortage Timeline

Solosec has experienced intermittent availability issues since its launch in 2017, but these have become more pronounced in recent years:

• 2017: FDA approval of Secnidazole (Solosec) for bacterial vaginosis in adult women. Initially marketed by Symbiomix Therapeutics, later acquired by Lupin Pharmaceuticals.
• 2021: FDA approved expanded indication for trichomoniasis and expanded age range to patients 12 years and older.
• 2023–2024: Increasing reports of pharmacy-level stockouts, driven by supply chain disruptions and growing prescribing volume.
• 2025–2026: Continued intermittent availability. Not listed on the FDA Drug Shortage Database, but real-world access remains inconsistent, particularly at chain pharmacies.

Prescribing Implications

Solosec's key clinical advantage is its single-dose oral regimen — a 2-gram packet of granules consumed with food, with no multi-day course to complete. This offers meaningful benefits for medication adherence, particularly in populations where treatment completion is a concern.

However, the current availability picture means that providers should:

• Verify pharmacy stock before prescribing when possible, or advise patients to confirm availability before leaving the office
• Include alternative options on the prescription (e.g., "if Solosec unavailable, substitute Metronidazole 500 mg BID x 7 days") where clinically appropriate
• Be prepared to discuss cost — patients may face sticker shock if they've never checked the cash price
• Document the clinical rationale for Solosec when prior authorization is required by insurers

Current Availability Picture

The challenge with Solosec availability is structural:

• Single manufacturer: Lupin Pharmaceuticals is the sole source. No authorized generic or competing brand exists.
• No generic Secnidazole: As of 2026, no ANDA for generic Secnidazole has been approved.
• Low pharmacy stocking rates: Because Solosec is dispensed as a single unit per patient, many pharmacies — especially chains — don't maintain regular inventory. This means even when the drug is in the supply chain, individual pharmacy locations may not have it.
• Distribution variability: Availability can vary significantly by region and distributor network. Independent pharmacies with different wholesale relationships may have better access.

The practical result: patients are often told their pharmacy "doesn't carry it" or "can't get it," even when the drug is technically available through the distributor.

Cost and Access Considerations

Cost is a significant barrier for many patients:

• Cash price: $290–$550 per single-dose packet (varies by pharmacy)
• Coupon card pricing: ~$290 via SingleCare and similar services
• Insurance coverage: Variable. Many plans require prior authorization or step therapy (e.g., trial of Metronidazole first). Some classify it as a specialty tier with higher copays ($30–$75+).
• Medicare Part D: Coverage depends on specific plan formulary. Many Part D plans do not include Solosec on their preferred formulary.

For comparison, generic alternatives are dramatically less expensive:

• Metronidazole (oral): $4–$15 for 7-day course
• Metronidazole (vaginal gel): $15–$40
• Clindamycin (vaginal cream): $10–$30
• Tinidazole (oral): $15–$50

Tools and Resources for Your Practice

Several tools can help you and your patients navigate Solosec access:

Medfinder for Providers

Medfinder offers real-time pharmacy inventory lookup. You or your staff can check which pharmacies in a patient's area have Solosec in stock before sending the prescription, reducing patient frustration and unnecessary pharmacy calls.

Savings and Assistance Programs

• Manufacturer savings: Check solosec.com for any current Lupin Pharmaceuticals savings programs
• Coupon cards: SingleCare, GoodRx, BuzzRx, and others may reduce the cash price
• Patient assistance: NeedyMeds.org and RxAssist.org maintain directories of patient assistance programs for uninsured or underinsured patients

Patient Education Resources

Consider directing patients to these resources:

• How to find Solosec in stock
• Alternatives to Solosec
• How to save money on Solosec

Alternative Therapies: A Quick Reference

When Solosec is unavailable or cost-prohibitive, the following alternatives are well-supported by clinical guidelines:

For Bacterial Vaginosis

• Metronidazole 500 mg PO BID x 7 days (first-line per CDC guidelines)
• Metronidazole 0.75% vaginal gel, 5 g intravaginally QD x 5 days
• Clindamycin 2% vaginal cream, 5 g intravaginally QHS x 7 days
• Tinidazole 2 g PO QD x 2 days or 1 g PO QD x 5 days

For Trichomoniasis

• Metronidazole 500 mg PO BID x 7 days (recommended for women per CDC)
• Tinidazole 2 g PO single dose

Note: Clindamycin is not effective against Trichomonas vaginalis.

Looking Ahead

Several developments could improve the Solosec access situation in the coming years:

• Generic competition: If and when generic Secnidazole is approved, it would dramatically improve both availability and pricing.
• Alternative single-dose therapies: Research continues on novel BV treatments, though none are imminent.
• Distribution improvements: Lupin Pharmaceuticals may expand distribution channels or implement direct-to-pharmacy programs.

In the meantime, proactive prescribing practices — confirming availability, discussing cost, and having backup plans — will give your patients the best experience.

Final Thoughts

Solosec remains a clinically valuable option for single-dose BV treatment, but real-world access in 2026 is inconsistent. By using tools like Medfinder for providers, discussing alternatives upfront, and helping patients navigate cost barriers, you can ensure that a supply chain issue doesn't delay effective treatment.

For a patient-facing companion to this article, see our Solosec shortage update for patients.